All In Biotech

Drug Trial Radar · NCT07884734

A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participants

A Phase 1, Open-Label, 2-Part Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of a CYP3A4 Inducer (Carbamazepine) or Inhibitor (Itraconazole) With Radiprodil in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 8, 2026

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
GRIN Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, 2-part study in healthy adult participants to evaluate the pharmacokinetics and safety of radiprodil when coadministered with either the CYP3A4 inducer carbamazepine or the CYP3A4 inhibitor itraconazole. Up to 36 participants will be enrolled, with approximately 18 participants in Part A and 18 participants in Part B.

Conditions

  • Healthy Adult Participants

Interventions

  • RadiprodilDrug

    Radiprodil administered orally as a single dose of 30 mg in Part A or 15 mg in Part B under fed conditions.

  • CarbamazepineDrug

    Carbamazepine administered orally twice daily at doses of 100 mg, 200 mg, and 300 mg in Part A to evaluate the effect of CYP3A4 induction on the pharmacokinetics of radiprodil.

  • Itraconazole (200 mg)Drug

    Itraconazole administered orally at 200 mg once daily in Part B to evaluate the effect of CYP3A4 inhibition on the pharmacokinetics of radiprodil.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUClast of Radiprodil - Part ATime frame: Part A: Day 1 through Day 19
  2. AUCinf of Radiprodil - Part ATime frame: Part A: Day 1 through Day 19
  3. Cmax of Radiprodil - Part ATime frame: Part A: Day 1 through Day 19
  4. AUClast of Radiprodil - Part BTime frame: Part B: Day 1 through Day 12
  5. AUCinf of Radiprodil - Part BTime frame: Part B: Day 1 through Day 12
  6. Cmax of Radiprodil - Part BTime frame: Part B: Day 1 through Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group (CCTMG)

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.